Eric Miller
Transplant Surgery · San Francisco, CANPI 1841559275
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,035 of the $4,322 with a category attached, or 70.2%. Intuitive Surgical accounts for 89.2% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $4,255, more than ten times the $23 reported in 2022.
Across 18 payments — averaging $240.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Histosonics, Inc.$230
- Procept Biorobotics Corporation$49
- Johnson & Johnson$36
- AstraZeneca$35
- Davol Inc.$34
- plus $83 from 4 others
What the payments were for
- Travel & lodging$2305%
- Food & beverage$1,05824%
- Education$3,03570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,855 |
| Histosonics, Inc. | 1 | $230 |
| Procept Biorobotics Corporation | 2 | $49 |
| Johnson & Johnson(2 entities) | 2 | $36 |
| AstraZeneca | 1 | $35 |
| Davol Inc. | 1 | $34 |
| Novartis | 1 | $33 |
| Tolmar Pharmaceuticals, Inc. | 1 | $23 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
| BD | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$3,000
- Da Vinci Surgical System$794
How this compares
$4,322 in reported general payments places this provider in the 65th percentile of 56 transplant surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 12 | $9,190 |
| Methenamine Hippurate | 33 | $2,100 |
| Tamsulosin Hcl | 71 | $818 |
| Finasteride | 48 | $733 |
| Oxybutynin Chloride ErOxybutynin Chloride | 30 | $485 |
| Oxybutynin Chloride | 12 | $294 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $140 |
| Cephalexin | 30 | $49 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in San Francisco
- Janet BellinghamSan Francisco$4K
- Assad HassounSan Francisco$237
- Garrett HisatakeSan Francisco$175
- John RobertsSan Francisco$3
- Elizabeth SquiersHalf Moon Bay$1.3M
- Myron TongPasadena$99K
- Robert RedfieldOrange$65K
- Yuri GenykLos Angeles$35K
- Angeles Baquerizola Jolla$28K
- Navpreet KaurLos Angeles$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.